Prime study finds the cost of GLP-1s continues to be a significant driver of total cost of care, which remained $4,490 higher in Year 3 compared to a matched control group
Prime study finds individuals enrolled in the program for six months who took GLP-1 drugs for obesity lost an average of 22.5 pounds, and 95% of patients remained on GLP-1 therapy
Research presented at AMCP 2026 shows how integrated pharmacy and medical benefits may reduce medical costs and health care resource utilization
Prime Therapeutics research presented at AMCP 2026 shows treatment for complex conditions benefit from case management support like Prime’s Care Specialists program
Research presented by Prime Therapeutics experts AMCP 2026 shows how patients with hereditary angioedema respond differently to treatment, and how Prime manages on-demand and preventive treatments
Recent research presented at AMCP 2026 shows treatment location affects cost and use. Here’s how Prime is poised to support patients.
A Prime Therapeutics research poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) explores the use of GLP-1 medications to treat obesity when paired with KeepWell™, a cardiometabolic care management solution
A Prime Therapeutics research poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) explores the cost impact of GLP-1 medications, offering critical insights for payers and providers
Prime presents studies on CAR T therapies, medical and pharmacy benefit integration, biologics, mental health parity and more
Studies on GLP-1 drugs, specialty therapies and more help improve affordability in health care
Login Portals
Compliance / Legal
Company
